Edward Rudd
Partner @ Juno Capital Partners
London, United Kingdom
Edward Rudd is a Series A investor at Juno Capital Partners in London focused on Software and Health Care. Edward focuses on sourcing investment opportunities and due diligence. His investment experience has included many University spinouts, primarily in the life sciences sector but also including nanotechnology and software. He is non executive director of Domainex Ltd and Biotronics 3D Ltd.Edward graduated from Oxford University and joined BZWwhere he worked in the investment management and equity capital markets divisions. He left to join KPMG in Birmingham where he qualified as a Chartered Accountant. From 2002 until the establishment of Longbow Capital he was an investment executive and Finance Director at an early stage venture capital firm in London.
- Total investments:
- 14
- Last investment:
- Lead investor:
- 43%
Last updated:
For AI agents: llms.txt
Industries Edward Rudd invests in
Stages Edward Rudd invests in
Countries Edward Rudd invests in
Investment Focus
Industry
- Software 2 (14%)
- Health Care 2 (14%)
- Biotechnology 2 (14%)
- SaaS 1 (7%)
- Medical 1 (7%)
Stage
- Series A 4 (29%)
- Seed 3 (21%)
- Series B 2 (14%)
- Funding Round 2 (14%)
- Angel 1 (7%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
|
|
Torsion delivers Confident Data Access Control. It helps you get control of who has access to what, why and when – among massive collections of files, folders and sites. Access to files and folders sprawls much faster than it is controlled. Constant sharing with little visibility or control of who has access to what, leads to significant securityand compliance challenges.Torsion integrates with your existing collaboration systems, working with business users to monitor and control access as circumstances constantly evolve. Working across Microsoft Teams, SharePoint, Office 365 and File Share systems – to improve data security and simplify compliance. Unlike traditional data governance tools, Torsion focusses on the people in the business, to help them use information securely. Business users, not IT, are best positioned to understand who needs access to their information, and so we empower them without slowing them down.Torsion’s unique solution is cloud-first, smooth to deploy and affordable for businesses of all sizes. | $1.3M / Seed / Jun 29, 2022 | |
|
|
Edozo makes the £multi-trillion commercial property sector more efficient at a time when organisations need to find competitive advantage. Our platform is already loved by hundreds of property firms including global brands such as CBRE and JLL. We consolidate best-in-class mapping, data and process automation technology on a single platform. | $2.6M / Aug 13, 2021 | |
|
|
Edozo makes the £multi-trillion commercial property sector more efficient at a time when organisations need to find competitive advantage. Our platform is already loved by hundreds of property firms including global brands such as CBRE and JLL. We consolidate best-in-class mapping, data and process automation technology on a single platform. | $2.8M / Seed / Aug 13, 2021 | |
|
|
Sky Medical Technology is a growth-stage bioelectronic medicine platform that completely redefines the way vascular related conditions are treated. The company has developed a neuromodulation therapy called OnPulse™, the first clinically proven bioelectronic compression technology to prevent and treat a wide range of acute and chronic circulatoryconditions. The first indications for the OnPulse wearable therapy are life threatening blood clots, swelling after orthopedic surgery, long term non-healing wounds, as well as applications for pro athletes to speed-up recovery time between games and during travel, conditions experienced by more than forty million people currently with unmet need. | $13.5M / Series B / Sep 01, 2017 | |
|
|
cloud.IQ is an AI and machine learning based automated conversion rate optimisation platform for e-commerce businesses. Powered by real-time data and analytics, the cloud.IQ technology works to optimise the customer journey without requiring any website changes, significantly growing online revenue. Co-founded in 2012 by James Critchley and PaulPhillips, cloud.IQ is headquartered in London with offices in Sydney, serving a global client list including Allianz, Boots, Bose, EE, Hearst Magazines, Samsung, TUI and more. For more information, visit www.cloud-iq.com. | $5.2M / Series B / Jul 31, 2017 | |
|
|
cloud.IQ is an AI and machine learning based automated conversion rate optimisation platform for e-commerce businesses. Powered by real-time data and analytics, the cloud.IQ technology works to optimise the customer journey without requiring any website changes, significantly growing online revenue. Co-founded in 2012 by James Critchley and PaulPhillips, cloud.IQ is headquartered in London with offices in Sydney, serving a global client list including Allianz, Boots, Bose, EE, Hearst Magazines, Samsung, TUI and more. For more information, visit www.cloud-iq.com. | $5.2M / Series A / Mar 09, 2017 | |
|
|
cloud.IQ is an AI and machine learning based automated conversion rate optimisation platform for e-commerce businesses. Powered by real-time data and analytics, the cloud.IQ technology works to optimise the customer journey without requiring any website changes, significantly growing online revenue. Co-founded in 2012 by James Critchley and PaulPhillips, cloud.IQ is headquartered in London with offices in Sydney, serving a global client list including Allianz, Boots, Bose, EE, Hearst Magazines, Samsung, TUI and more. For more information, visit www.cloud-iq.com. | $2.2M / Angel / Sep 02, 2016 | |
|
|
Sky Medical Technology is a growth-stage bioelectronic medicine platform that completely redefines the way vascular related conditions are treated. The company has developed a neuromodulation therapy called OnPulse™, the first clinically proven bioelectronic compression technology to prevent and treat a wide range of acute and chronic circulatoryconditions. The first indications for the OnPulse wearable therapy are life threatening blood clots, swelling after orthopedic surgery, long term non-healing wounds, as well as applications for pro athletes to speed-up recovery time between games and during travel, conditions experienced by more than forty million people currently with unmet need. | $15M / Series A / Feb 01, 2015 | |
|
|
Sky Medical Technology is a growth-stage bioelectronic medicine platform that completely redefines the way vascular related conditions are treated. The company has developed a neuromodulation therapy called OnPulse™, the first clinically proven bioelectronic compression technology to prevent and treat a wide range of acute and chronic circulatoryconditions. The first indications for the OnPulse wearable therapy are life threatening blood clots, swelling after orthopedic surgery, long term non-healing wounds, as well as applications for pro athletes to speed-up recovery time between games and during travel, conditions experienced by more than forty million people currently with unmet need. | $13M / Feb 01, 2014 | |
|
|
Get your NearDesk card today!to access a growing network“By embracing flexible working we cut our office costs enough to hire two more staff. We still meet as a team regularly but travel less, get way more done and all enjoy life more.”Flexible working is a hot-topic at the moment as companies look to attract and retain talent whilst cuttingcosts. | $1.3M / Series A / Nov 18, 2013 | |
| See all 14 investments → | |||
Co-Investors
About Juno Capital Partners
Juno Capital is an innovative specialist alternative asset manager to a network of wealthy individuals and family offices – the “Syndicate Members”. Established in 2011, we target asset classes overlooked by mainstream asset managers and private banks, including venture capital, asset backed fixed income and niche property.Juno Capital wasfounded by Julian Hickman and Edward Rudd in 2011.
Juno Capital Partners Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Edward Rudd
Partner
|
|||
|
Claire Corbin
Partner & Operations Manager, Venture Investment
|
|||
|
Julian Hickman
Partner
|
|||
|
Malcolm Le May
Partner
|
|||
|
Nigel Rudd
Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Edward Rudd invest in?
Edward Rudd invests primarily in Software, Health Care and Biotechnology startups, most often at Series A and Seed stage. Most of the 14 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Edward Rudd last invest?
The most recent investment recorded for Edward Rudd closed in Jun 2022. Shizune tracks 14 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!